1. Home
  2. IRTC
  3. Earnings

AI Earnings Predictions for iRhythm Technologies Inc. (IRTC)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

SELL

1-Day Prediction

-1.07%

$132.56

0% positive prob.

5-Day Prediction

-8.35%

$122.81

0% positive prob.

20-Day Prediction

-7.77%

$123.59

0% positive prob.

Price at prediction: $134.00 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 SELL -1.07% -8.35% -7.77% 100.0% Pending
Q2 2026 BUY +4.63% +9.60% +5.58% 98.5% Pending
Q1 2026 SELL -0.42% -9.76% -7.86% 100.0% -3.32%
Q4 2025 SELL +0.34% -9.42% -4.85% 100.0% -11.77%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 5, 2026 · 100% conf.

AI Prediction SELL

1D

-1.07%

$132.56

Act: -30.53%

5D

-8.35%

$122.81

20D

-7.77%

$123.59

Price: $134.00 Prob +5D: 0% AUC: 1.000
0001388658-26-000093

EX-99.1

2 irtcq32026ex991pressrelease.htm

EX-99.1

Document

Exhibit 99.1

iRhythm Holdings Announces Third Quarter 2026 Financial Results

SAN FRANCISCO, November 5, 2026 -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2026.

Third Quarter 2026 Financial Highlights

•Revenue of $221.6 million, a 14.9% increase compared to third quarter 2025

•Gross margin of 74.2%, a 310-basis point increase compared to third quarter 2025

•GAAP net loss of $29.9 million, a $24.6 million increase in net loss compared to third quarter 2025

•Adjusted EBITDA and adjusted EBITDA margin of $51.2 million and 23.1%, respectively, a $29.6 million and 1,190-basis point improvement, respectively, compared to third quarter 2025

•Unrestricted cash, cash equivalents, and marketable securities of $560.7 million as of September 30, 2026

•Increased fiscal year 2026 revenue guidance to $890 million to $895 million and adjusted EBITDA margin guidance to 15.5% to 16.0%

Recent Operational Highlights

•Delivered another strong quarter, driven by healthy volume-led revenue growth of Zio Monitor and robust margin expansion, with broad-based momentum across cardiology, primary care, innovative channels and international markets

•Completed the acquisition of VitalConnect on October 5, 2026, broadening our cardiac monitoring portfolio with an immediate FDA-cleared mobile cardiac telemetry offering, advancing our multi-vitals strategy, and expanding our addressable market across the continuum of care

•Published three large-scale real world studies demonstrating product superiority of Zio AT (CAMELOT-ALERT1), Zio Long-Term Continuous Monitoring (EXCALIBUR2), and improvements in Zio Monitor performance and diagnostic yield compared with Zio XT3 in over 1.7 million total patients

•Submitted FDA 510(k) applications for pediatric use with our Zio Monitor long-term continuous monitoring business

•Closed a new $300 million senior secured revolving credit facility on November 3, 2026, providing additional liquidity to support our long-term growth objectives

“Our third quarter results reflect the continued strength of our core business. Demand for Zio Monitor remains robust, exceeding our expectations in the quarter, driven by volume growth across care settings and channels. We also continued to take meaningful steps forward with significant margin expansion, and consistent execution against our strategic priorities,” said Quentin Blackford, President and Chief Executive Officer of iRhythm. “With the acquisition of VitalConnect now closed, we are encouraged by the early opportunities we see to broaden our capabilities and serve more patients within the ambulatory cardiac monitoring market and across the continuum of care. With an immediate FDA-cleared mobile cardiac telemetry device, we are excited to be able to offer the marketplace a best-in-class MCT portfolio of options. We remain focused on advancing innovation, expanding access to Zio, and investing in the growth initiatives that we believe will create durable value for patients, clinicians, and stockholders.”

Third Quarter 2026 Financial Results

Revenue for the third quarter of 2026 was $221.6 million, up 14.9% from $192.9 million during the same period in 2025. The increase was driven primarily by sustained volume demand across our customer base, reflecting continued strength in our core business and contributions from newer growth channels.

Gross profit for the third quarter of 2026 was $164.5 million, up 20.0% from $137.1 million during the same period in 2025, while gross margin was 74.2%, a 310-basis point improvement compared to the third quarter of 2025. The increase in gross profit was primarily due to increased volume of Zio services, as well as a one-time benefit from tariff refunds of approximately $3.1 million. The increase in gross margin was primarily driven by continued operational efficiencies, product mix, a tariff refund one-time benefit, and disciplined execution.

Exhibit 99.1

Operating expenses for the third quarter of 2026 were $197.0 million, compared to $145.6 million for the same period in 2025. Adjusted operating expenses for the third quarter of 2026 were $138.6 million, compared to $141.4 million during the same period in 2025. The decrease in adjusted operating expenses, period over period, reflects a disciplined approach to investment, as we funded key growth initiatives while thoughtfully managing costs across the broader organization.

GAAP net loss for the third quarter of 2026 was $29.9 million, or net loss per diluted share of $0.90, compared with GAAP net loss of $5.2 million, or net loss per diluted share of $0.16, for the same period in 2025. Adjusted net income for the third quarter of 2026 was $27.8 million, or net income per diluted share of $0.82, compared wi

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 6, 2026 · 98% conf.

AI Prediction BUY

1D

+4.63%

$134.06

Act: -0.22%

5D

+9.60%

$140.42

20D

+5.58%

$135.27

Price: $128.12 Prob +5D: 99% AUC: 1.000
0001388658-26-000070

EX-99.1

2 irtcq22026ex991pressrelease.htm

EX-99.1

Document

Exhibit 99.1

iRhythm Holdings Announces Second Quarter 2026 Financial Results

SAN FRANCISCO, August 6, 2026 -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2026.

Second Quarter 2026 Financial Highlights

•Revenue of $224.2 million, a 20.1% increase compared to second quarter 2025

•Gross margin of 72.8%, a 160-basis point increase compared to second quarter 2025

•Net loss of $0.4 million, a $13.8 million improvement compared to second quarter 2025

•Adjusted EBITDA and adjusted EBITDA margin of $43.3 million and 19.3%, respectively, a $27.6 million and 1090-basis point improvement, respectively, compared to second quarter 2025

•Unrestricted cash, cash equivalents, and marketable securities of $591.3 million as of June 30, 2026

•Increased fiscal year 2026 revenue guidance to $880 million to $890 million and adjusted EBITDA margin guidance to 13.0% to 14.0%

Recent Operational Highlights

•Delivered another strong quarter, demonstrated by robust volume led revenue growth and expanded margins, with continued momentum across cardiology, primary care, innovative channels, and international markets

•Entered into a definitive agreement to acquire Vital Connect, Inc. ("VitalConnect"), a privately held company that offers complementary ambulatory cardiac monitoring technology, for total consideration of approximately $287.5 million. Upon closing, the transaction is expected to immediately expand iRhythm's addressable market and advance its evolution into a broader cardiac monitoring and intelligence platform

•Achieved FDA clearance of our third-generation algorithm, which is expected to reduce clinician review time by approximately 50% over time and drive approximately $100 million of cumulative cost savings over the next five years

•Continued to scale our Predictive Arrhythmia Solutions™ footprint with Desert Oasis Health Care, an affiliate of Heritage Provider Network, supporting earlier identification of patients who may benefit from cardiac evaluation and monitoring through AI-driven predictive analytics

•Recognized by Newsweek in 2026 as one of America’s Greatest Workplaces for Leadership and among the World’s Greenest Companies, reflecting iRhythm’s continued commitment to strong leadership, workplace culture, and sustainability

“Our second quarter results reflect strong execution across the business, with broad-based growth, meaningful margin expansion, and continued progress against our strategic priorities,” said Quentin Blackford, President and Chief Executive Officer of iRhythm. “We are driving adoption across an increasingly diverse set of care settings and channels, including primary care, while continuing to invest in the capabilities that we believe will shape the future of healthcare. We are also thrilled to have entered into a definitive agreement to acquire VitalConnect, a transaction we believe will allow us to serve more patients, while also creating long-term value for clinicians and stockholders.”

Second Quarter 2026 Financial Results

Revenue for the second quarter of 2026 was $224.2 million, up 20.1% from $186.7 million during the same period in 2025. The increase was driven primarily by sustained volume demand across our customer base, reflecting continued strength in our core business and contributions from newer growth channels.

Gross profit for the second quarter of 2026 was $163.2 million, up 22.8% from $132.9 million during the same period in 2025, while gross margin was 72.8%, a 160-basis point improvement compared to second quarter 2025. The increase in gross profit was primarily due to increased volume of Zio services. The increase in gross margin was primarily driven by continued operational efficiencies, product mix, and scale benefits from higher volumes.

Operating expenses for the second quarter of 2026 were $165.7 million, compared to $151.6 million for the same period in 2025. Adjusted operating expenses for the second quarter of 2026 were $145.0 million, compared to $145.2 million during the same period in 2025. The decrease in adjusted operating expenses, period over period, reflects a disciplined approach to investment, as we funded key growth initiatives while thoughtfully managing costs across the broader organization.

Exhibit 99.1

GAAP net loss for the second quarter of 2026 was $0.4 million, or net loss per diluted share of $0.01, compared with GAAP net loss of $14.2 million, or net loss per diluted share of $0.44, for the same period in 2025. Adjusted net income for the second quarter of 2026 was $19.3 million, or net income per diluted share of $0.58, compared with an adjusted net loss of $10.2 million, or net loss per diluted share of $0.32, for the same period in 2025. The improvement was primarily driven by our

2026
Q1

Q1 2026 Earnings

8-K SELL

Apr 30, 2026 · 100% conf.

AI Prediction SELL

1D

-0.42%

$128.62

Act: -7.91%

5D

-9.76%

$116.56

Act: -3.32%

20D

-7.86%

$119.01

Act: -11.83%

Price: $129.16 Prob +5D: 0% AUC: 1.000
0001388658-26-000038

EX-99.1

2 irtcq12026ex991pressrelease.htm

EX-99.1

Document

Exhibit 99.1

iRhythm Holdings Announces First Quarter 2026 Financial Results

SAN FRANCISCO, April 30, 2026 -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2026.

First Quarter 2026 Financial Highlights

•Revenue of $199.4 million, a 25.7% increase compared to first quarter 2025

•Gross margin of 70.9%, a 210-basis point increase compared to first quarter 2025

•Net loss of $13.9 million, a $16.8 million improvement compared to first quarter 2025

•Adjusted EBITDA and adjusted EBITDA margin of $14.1 million and 7.1%, respectively, a $16.7 million and 880-basis point improvement, respectively, compared to first quarter 2025

•Unrestricted cash, cash equivalents, and marketable securities of $549.6 million as of March 31, 2026

•Increased fiscal year 2026 revenue guidance to $875 million to $885 million and adjusted EBITDA margin to 12.0% to 13.0%

Recent Operational Highlights

•Delivered another strong quarter, demonstrated by robust volume led revenue growth and expanded margins, with continued momentum across cardiology, primary care, innovative channels, and international markets

•Presented data at ACC and HRS further demonstrating the benefits of iRhythm’s Zio® ambulatory ECG portfolio across multiple patient populations as company launches new digital education platform

“We delivered a strong start to 2026, with continued revenue growth reflecting durable demand for our platform and increasing adoption across multiple care settings,” said Quentin Blackford, President and Chief Executive Officer of iRhythm. “We are increasingly diversified across channels, with meaningful contributions from Zio monitor, Zio AT, innovative partnerships, and international markets. As we advance our AI-enabled capabilities and expand into earlier detection, we believe we are unlocking a significantly larger opportunity to improve patient outcomes while providing an integrated solution that lowers the total cost of cardiac care.”

First Quarter 2026 Financial Results

Revenue for the first quarter of 2026 was $199.4 million, up 25.7% from $158.7 million during the same period in 2025. The increase was driven primarily by sustained volume demand across our customer base, reflecting continued strength in our core business and contributions from newer growth channels.

Gross profit for the first quarter of 2026 was $141.4 million, up 29.4% from $109.2 million during the same period in 2025, while gross margin was 70.9%, a 210-basis point improvement compared to first quarter 2025. The increase in gross profit was primarily due to increased volume of Zio services. The increase in gross margin was primarily driven by continued operational efficiencies, as well as scale benefits from higher volumes.

Operating expenses for the first quarter of 2026 were $157.5 million, compared to $141.8 million for the same period in 2025. Adjusted operating expenses for the first quarter of 2026 were $153.5 million, compared to $140.4 million during the same period in 2025. The increase in adjusted operating expenses, period over period, was driven by an increase in volume-related costs to serve, litigation-related expenses and investments to drive future revenue growth.

Net loss for the first quarter of 2026 was $13.9 million, or a net loss of $0.43 per diluted share, compared with net loss of $30.7 million, or net loss of $0.97 per diluted share, for the same period in 2025. Adjusted net loss for the first quarter of 2026 was $11.3 million, or net loss of $0.35 per diluted share, compared with an adjusted net loss of $30.3 million, or net loss of $0.95 per diluted share, for the same period in 2025. The decrease in net loss was primarily driven by our revenue growth and operating leverage achieved through implementation of efficiency initiatives.

Unrestricted cash, cash equivalents, and marketable securities were $549.6 million as of March 31, 2026.

Exhibit 99.1

2026 Annual Guidance

For the full year 2026, iRhythm expects revenue between $875 million and $885 million and adjusted EBITDA margin between 12% and 13%, reflecting continued volume-led growth, gross margin expansion, and operating leverage while maintaining disciplined investment in innovation and market expansion.

Webcast and Conference Call Information

iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT/4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.

About iRhythm Holdings, Inc.

iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data a

About iRhythm Technologies Inc. (IRTC) Earnings

This page provides iRhythm Technologies Inc. (IRTC) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on IRTC's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: